Juno Jerold Joel

Juno Jerold Joel

Auto-generated profile, based on publicly available information

Juno Jerold Joel

Department of Pharmacy Practice, NITTE (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Le Pharmacien Hospitalier et Clinicien
Verified
Journal Article
Closed access
AJAnisty Maria Joy
Anisty Maria Joy
NUNandakumar Up
Nandakumar Up
SCSharad Chand
Sharad Chand
JKJayaram Shetty K
Jayaram Shetty K
SGSophia M. George
Sophia M. George
JJJuno J. Joel
Juno J. Joel

18 July 2024 in Discover Medicine
Verified
Journal Article
Open access
PDF file
KSK. Sreeraj
K. Sreeraj
VRV. U. Risana
V. U. Risana
SMSandra Rose Mathew
Sandra Rose Mathew
SSSauparnika Soman
Sauparnika Soman
RCRompicherla Narayana Charyulu
Rompicherla Narayana Charyulu
SSS. M. Sarin
S. M. Sarin
The use of topical corticosteroids (TCs) in pediatric patients is a common therapeutic approach for various dermatological conditions. However, their application can lead to a spectrum of adverse drug reactions (ADRs), from localized skin changes to systemic effects. Due to factors such as thinner skin, enhanced cutaneous absorption, and developing organ systems, pediatric populations are particularly vulnerable to TCs-led ADRs. The most common ADRs associated with the use of TCs in the pediatric population include skin atrophy, striae, and telangiectasia. Other less common ADRs include allergic contact dermatitis, perioral dermatitis, and systemic effects such as suppression of the hypothalamic–pituitary–adrenal (HPA) axis, etc. To minimize the possibility of ADRs and unwanted medication reactions, rational and safe use of TCs shall be promoted. Clinical Pharmacists (CPs) play a pivotal role in ensuring appropriate and safe utilization of TCs in pediatric patient care. CPs collaborate with healthcare practitioners to design individualized treatment regimens considering factors such as age, skin type, and medical history. They also educate patients and caregivers on proper TCs application techniques, therapy duration, and potential side effects, thereby facilitating better adherence and treatment outcomes. Clinical research specific to pediatric populations is essential to provide precise insights into TCs effectiveness and safety, accounting for age-related variations and long-term consequences. TCs represent a valuable tool in pediatric dermatology, but their use requires careful consideration of the risks and benefits, active involvement of CPs, regulatory measures, and ongoing research to optimize therapy outcomes and safety in pediatric patients.

28 December 2023 in Endocrine
Verified
Journal Article
Closed access
PDF file
BSBipin Shaji
Bipin Shaji
JJJuno Jerold Joel
Juno Jerold Joel
RSRaghava Sharma
Raghava Sharma
SSShraddha Shetty
Shraddha Shetty
CSC. S. Shastry
C. S. Shastry
UMUday Venkat Mateti
Uday Venkat Mateti

23 August 2024 in Journal of Young Pharmacists
Verified
Journal Article
Open access
PDF file
BSBipin Shaji
Bipin Shaji
JJJuno Jerold Joel
Juno Jerold Joel
RSRaghava Sharma
Raghava Sharma
Bipin Shaji1, Juno Jerold Joel1 and Raghava Sharma2 Author informationArticle notesCopyright and License informationCitations 1Department of Pharmacy Practice, NITTE (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Mangalore, INDIA 2Department of General Medicine, NITTE (Deemed to be University), KS Hegde Medical Academy (KSHEMA), Mangalore, INDIA Corresponding author. Correspondence: Dr. Juno Jerold Joel, M

1 January 2019 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
PDF file
CSChinnu Scaria
Chinnu Scaria
ASAnanthu Satheesh
Ananthu Satheesh
PPPooja Prabhakar
Pooja Prabhakar
JJJuno J. Joel
Juno J. Joel
SKShishir Kumar
Shishir Kumar
Objective To identify the adverse drug reactions caused by psychotropic drugs and to evaluate the causality, severity, preventability and management of those Adverse Drug Reactions (ADRs). Methods A prospective observational study was carried out in hospitalised patients with psychiatric disorders. All the in-patients prescribed with psychotropic drugs were enrolled in the study and followed regularly for the identification of ADRs. Identified ADRs were assessed for causality, severity and preventability using various scales. Approaches towards the management of the ADRs and the patient outcomes were analysed. Results A total of 200 patients were monitored, of which 79 ADRs were identified from 56 patients. The most commonly reported ADRs were tremor (18.98%) followed by drowsiness (17.72%). Olanzapine was found to be associated with more number of ADRs (29.11%) followed by Clozapine (12.65%). Causality assessment using World Health Organisation-Uppsala Monitoring Centre (WHO-UMC) scale showed that most of the ADRs were probable (62.02%) and possible (37.97%). Severity assessment revealed that 54.42% of ADRs were found to be moderately severe. 48.10% of ADRs were definitely preventable and 44.30% were probably preventable. Assessment on the management of ADRs says that most of them were resolved by specific treatment approach to the reaction. Conclusion The end results of the study created the evidence on the incidence of ADRs in patients prescribed with psychotropic drugs. The study emphasises on monitoring of those drugs that are considered to have high risk in developing ADRs. Thus, it can influence to a chance of preventing or reducing an unwanted reaction.

1 December 2021 in Le Pharmacien Hospitalier et Clinicien
Verified
Journal Article
Open access
JJJestin George Joseph
Jestin George Joseph
SPSantosh Prabhu
Santosh Prabhu
SCSharad Chand
Sharad Chand
DRDaniel Anila Roy
Daniel Anila Roy
UNU.P. Nandakumar
U.P. Nandakumar
JJJuno J. Joel
Juno J. Joel